Zydus Lifesciences in-licenses critical drug MonoFerric for CKD patients from Pharmacosmos A/S of Denmark

MonoFerric is available in over 30 countries including US and Europe and over 28 million doses have been administered since launch.

Speaking on the development Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd. said, "Iron Deficiency is a severe healthcare challenge and also impacts the quality of life more so in CKD patients. With this introduction, we bring a novel solution to these patients and with our strong lastmile delivery, we will enable access to this critical therapy."

Zydus group is headquartered in Ahmedabad, India. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.

Zydus' global business has a strong presence in the regulated markets of the US, Europe (France and Spain) and in the high profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide.

Zydus is amongst the top players in the Nephrology segment with a super-specialty portfolio with brands like Oxemia, Zyrop, Renocrit, Kbind, Grafalon, Tacromus and Mycomune.

Read also: Zydus Lifecsciences begins Desidustat Phase IV trial in patients with CKD induced anemia

Read also: Zydus Lifesciences bags USFDA nod for Ivermectin Cream for treatment of inflammatory lesions of rosacea